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Abstract
The rapid expansion of commercially available fermented food products raises important safety issues particularly when
infant food is concerned. In many cases, the activity of the microorganisms used for fermentation as well as what will be the
immunological outcome of fermented food intake is not known. In this manuscript we used complex in vitro, ex-vivo and in
vivo systems to study the immunomodulatory properties of probiotic-fermented products (culture supernatant and
fermented milk without live bacteria to be used in infant formula). We found in vitro and ex-vivo that fermented products
of Lactobacillus paracasei CBA L74 act via the inhibition of proinflammatory cytokine release leaving anti-inflammatory
cytokines either unaffected or even increased in response to Salmonella typhimurium. These activities are not dependent on
the inactivated bacteria but to metabolic products released during the fermentation process. We also show that our in vitro
systems are predictive of an in vivo efficacy by the fermented products. Indeed CBA L74 fermented products (both culture
medium and fermented milk) could protect against colitis and against an enteric pathogen infection (Salmonella
typhimurium). Hence we found that fermented products can act via the inhibition of immune cell inflammation and can
protect the host from pathobionts and enteric pathogens. These results open new perspectives in infant nutrition and
suggest that L. paracasei CBA L74 fermented formula can provide immune benefits to formula-fed infants, without carrying
live bacteria that may be potentially dangerous to an immature infant immune system.
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Introduction
In the initial years of human life the microbiota is established
and several environmental factors contribute to its generation,
including nutrition [1,2]. The microbiota then plays a major role
in the development of the immune system [3,4]. Thus the
interplay between nutrition, microbiota and immune cells is
decisive for the subsequent health of the infant [5].
Exclusive breast-feeding is recommended from birth to 6
months of age [6,7]. Breast milk is involved in the development
of a bifidobacteria-enriched microbiota [8], in protection against
potentially infectious agents [9] and the correct development of
secondary lymphoid organs and the immune system [10]. Infant
formulae are intended to serve as a substitute for breast milk in
infants who cannot be fed at breast, should not receive breast milk,
or for whom breast milk is not available [11].
It is known that infant formula does not recapitulate many of
the effects of breast-feeding as it does not impact on thymus size
[10] or microbiota composition [8].
Although human milk represents the gold standard, at present
no infant formula is able to reproduce the whole composition and
daily variability of human milk. Recent developments in infant
formulae have therefore been targeted towards reproducing the
functional effects, rather than the qualitative composition, of
human milk [12].
Even though more evidence on clinical trials is required,
fermented infant formula (FIF) without live bacteria has been
shown to be beneficial for several aspects of the well-being of
infants [13]. It has been shown that FIF administration in infants
can increase the amount of bifidobacteria in the feces and fosters
the development of poliovirus-specific IgAs in response to
Pentacoq vaccination, as compared to infants treated with
standard non-fermented formula (SF) [14]. Another study
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e87615
compared three groups of term neonates: 30 newborns were
breast-fed and 60 were randomized to receive either FIF or SF.
Infants were followed up for 4 months. They showed that breast-
fed and FIF treated infants had comparable thymus indexes and
lower fecal pH than SF-treated infants, suggesting that FIF may
have similar effect to maternal milk [15]. Another study tested the
effect of long-term administration on 971 infants (4–6 months of
age) of FIF or SF with a similar nutritional composition on
incidence or severity of acute diarrhea [16]. They found that there
was no difference in the number or duration of diarrhea episodes,
but there was a reduction in the severity of the episodes in the FIF
group, including fewer medical consultations and fewer changes to
other formulas [16]. Similarly, a randomized clinical trial
compared long term treatment with FIF or SF of newborns with
high risk of allergy until the age of 1 year old. While there was no
difference in the proportion of infants affected by cow’s milk
allergy, infants administered FIF had reduced positive skin prick
tests to cow’s milk. FIF seems to be beneficial also in pre-term
infants. While there was no major difference in the anthropometric
data, pre-term infants treated with FIF displayed reduced
abdominal distension from the second week of treatment [17].
Differently from term infants, there was no bifidogenic property of
the FIF and secreted IgAs were increased in FIF treated infants,
but only if the infants had been partially breast-fed, suggesting that
FIF can boost the maternal IgA response [17].
Hence, FIF has been shown to be safe, to have similar
nutritional properties of standard formula, and to mimic some
effects of maternal milk, in vivo. However, several bacteria can be
used to ferment milk, including probiotics, bacteria considered to
be beneficial to the host. However, the choice of probiotics to be
used should not be arbitrary as each strain may produce specific
metabolites in the fermented product with distinctive immuno-
modulatory properties [18]. For instance, when we compared the
activity of several Lactobacilli and their metabolic products - that we
called postbiotic [19] - on the immune system, we found that each
strain has very peculiar characteristics [19,20,21]. We found that
Lactobacillus plantarum v299 has detrimental effects due to its
immunostimulatory properties in mice and on healthy human
intestinal tissue [20,21], while LGG and L. paracasei B21090 can be
detrimental on inflamed tissues like those coming from patients
with inflammatory bowel disease [20]. By contrast, the activity of
postbiotics is very safe also on inflamed tissues presumably because
postbiotics lack the microbe associated molecular patterns that
may further activate inflamed tissues [20].
In this manuscript, in the attempt to define the immunomod-
ulatory properties of fermented milk powder preparations for
infant formula without living bacteria, we analyzed the activity of
metabolic products released by Lactobacillus paracasei CBA L74
during fermentation of culture media or milk for infant formula.
We studied their properties in vitro, on one of the most important
immune target (the dendritic cells, DCs) that are the initiators of
immunity or tolerance; ex-vivo, using an organ culture model set up
in our laboratory and in vivo in mice, during inflammation (colitis)
or infection (Salmonella infection).
Materials and Methods
Mice and bacterial strains
C57/BL6 mice were purchased from Charles River laborato-
ries. All mice were maintained in microisolator cages in a specific
pathogen-free animal facility. All experiments were performed in
accordance with the guidelines established in the Principles of
Laboratory Animal Care (directive 86/609/EEC) and approved
by the Italian Ministry of Health.
Lactobacillus paracasei CBA L74 (Heinz Italia SpA, Latina, Italy),
International Depository Accession Number LMG P-24778 was
grown in MRS broth (Biokar diagostics) in semi-anaerobic
conditions.
Salmonella enterica serovar typhimurium strain SL1344 (FB62)
was provided by G. Dougan (The Wellcome Trust Sanger
Institute, UK) and grown in LB broth.
CFU numbers were controlled by plating.
Lactobacillus paracasei CBA L74 and Salmonella FB62 supernatants
were obtained growing bacteria to OD600 = 0,6 in MRS and LB
respectively and filtering the resulting medium.
Cells and reagents
DCs were derived from human peripheral blood monocytes
selected with anti-CD14 antibodies coupled to magnetic beads
(Miltenyi, Bologna, Italy). CD14+ cells were incubated for 6 days
in complete medium containing granulocyte-macrophage colony
stimulating factor (GM-CSF, 5 ng/mL; BD Biosciences) and
interleukin-4 (2,5 ng/mL; BD Biosciences) in order to obtain
immature MoDCs.
MoDCs were incubated with either Salmonella FB62 (MOI 10:1
bacteria:DC) or Lactobacillus paracasei CBA L74 (MOI 10:1) for
1 hour in the presence of 2% LB, MRS, CBA L74 supernatant (in
MRS) or FB62 supernatant. After extensive wash cells were
incubated for 24 hours in the presence of gentamicin (100 mg/ml).
Supernatants were tested for cytokine abundance and cells were
analyzed by FACS for activation and maturation markers: HLA-
DR FITC (BD) and CD83 APC (BD) respectively.
Milk powders
Milk products in powder were provided by HJ Heinz (Heinz
Italia SpA, Latina, Italy).
The fermented milk was prepared from skim milk fermented by
Lactobacillus paracasei CBA L74 (Heinz Italia SpA, Latina, Italy),
International Depository Accession Number LMG P-24778. The
fermentation is started in the presence of 106 bacteria, reaching
108 colony-forming units/ml after a 15-hour incubation at 37uC.
After heating at 85uC for 20 seconds, in view of inactivating the
live bacteria, the formula is spray-dried. The final fermented milk
powder (FM) contains bacterial bodies and fermentation products.
The control (non-fermented milk, NFM) consists of skimmed
milk powder with the same basal nutrient composition of
fermented milk powder (grams per 100 g): proteins, 35; lipids, 1;
carbohydrates, 54.
Milk powders were resuspended at 1,41 g/100 ml in boiling
water.
Preparation of the control and fermented milk diets
The diets (control and fermented milk) had similar nutrient
composition and were prepared as pellets at Mucedola, Settimo
Milanese, Italy. The diets were a mixture of 95% standard rat/
mice chow ref. 4RF21 (Mucedola, Settimo Milanese, Italy) and
5% of the fermented milk or non-fermented milk, respectively.
Ex-vivo organ culture
The protocol developed in the lab by Tsilingiri K. et al. [20] for
human intestinal explant culture was modified for murine colon
tissue. Briefly: 25 mm2 chunks of murine colon were fixed to the
cylinder. Tissue was incubated with non-fermented and fermented
milk inside the cylinder for 1 hour at 37uC 5% CO2 and then
infected with 102 CFU FB62 resuspended in 50 ml of the
respective preparation. After 2 hours at 37uC 5% CO2 infection
medium was removed and gentamicin (100 mg/ml) added in the
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culture medium. Tissues were incubated for 24 hours in oxygen
chamber, then culture media were analysed for cytokine
production and tissues fixed for paraffin embedding and histolog-
ical evaluation.
DSS colitis
Mice were administered intragastrically for 14 consecutive days
(from day -2 to day 11) with 200 ml of vehicle, MRS, live CBA
L74, supernatant of CBA L74, non-fermented milk or fermented
milk. When special diets were used mice were fed with modified
diet from day 210 until the end of the experiment.
Acute colitis was induced supplementing drinking water with
DSS 3% (w/v) for 8–9 days. Recovery in plain water was allowed
until the end of the experiment.
Body weight and survival were assessed daily.
Salmonella survival
After receiving modified diet for 10 days mice were intragas-
trically infected with 106 CFU FB62 in 200 ml carbonate buffer.
Survival was assessed daily.
Histological analysis
4 mm sections from colon swiss rolls were stained with
Hematoxylin-Eosin (HE) standard protocol. Histological evalua-
Figure 1. Lactobacillus paracaseii CBA L74 supernatant has anti-inflammatory properties on MoDCs. MoDCs were infected with either
Salmonella SL1344 (MOI 10:1) or Lactobacillus CBA L74 (MOI 10:1) for 1 hour in medium without antibiotics or in the presence of 2% LB, MRS, FB62
supernatant (Sn FB62) or CBA L74 supernatant in MRS (Sn CBA L74). After washing and 24 h incubations in medium with antibiotics cytokine
abundance was evaluated. A. Concentrations of IL-12p70 and IL-10 as determined by ELISA and CBA assays respectively. B. The % of response relative
to FB62 infected MoDCs is shown after grouping six experiments together. C. Anti-inflammatory index calculated as ratio of IL-10/IL12p70
concentrations. * p,0,05; *** p,0,001.
doi:10.1371/journal.pone.0087615.g001
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tion of the grade of colitis was performed according to the
following histological grading system: 0 normal colonic mucosa; 1
minimal to mild inflammation restricted to the mucosa; 2
moderate inflammation in the mucosa, only occasionally extend-
ing to the submucosa; 3 moderate to severe inflammation
involving the mucosa with shortening or loss of the crypts,
extending into the submucosa and occasionally into the tunica
muscularis; 4 severe transmural inflammation in the mucosa,
submucosa, tunica muscularis, and subserosa, usually associated
with mucosal ulceration. Additionally, the number of lymphoid
aggregates was counted and the grade of colon edema (0= absent;
1 =minimal; 2 =mild; 3 =moderate; 4 = severe) was evaluated.
For each colon also the total number of ulcers and the number of
healing ulcers (i.e. re-epithelialized ulcers) were counted. Accord-
ing to their size, ulcers were classified as follows: small = ,10
crypts (or ,1 field at 400x); medium =10–20 crypts (,1 field at
100x) in width; large =.20 crypts (.1 field at 100x) in width.
Arbitrarily, a value of 1 was assigned to each small ulcer, a value of
2 to each medium ulcer, and a value of 4 to each large ulcer. The
total ulcer score was then calculated for each colon as follows:
Total ulcer score = no. of small ulcers*1+ no. of medium
ulcers*2+ no. of large ulcers*4.
Cytokine measurements
IL-10, IL-6, KC and TNF-a concentrations were determined by
Cytokine bead array (Becton Dickinson) and IL-12p70 concen-
tration was determined by commercially available ELISA (R&D
systems). Optical densities were measured on a Bio-Rad Dynatech
Laboratories ELISA reader at a wavelength of 450 nm (Hercules,
CA, USA). CBA-associated Cytofluorimetry was measured by
FACS array (Becton Dickinson).
Anti-inflammatory index was calculated as ratio between IL-10
and IL-12% of response relative to FB62 stimulation.
RT-qPCR assay
Colons were homogenised in 500 ul of TRIzol (Invitrogen).
RNA was extracted adding 100 ul of chloroform, precipitating the
acqueous phase with 300 ul of 70% ethanol and purifying RNA
with RNeasy Mini Kit (QIAGEN). RNA was retro-transcribed
with ImProm-II Reverse Transcriptase kit (Promega) following
manufacturer’s instruction. qPCR assay was performed with Fast
Sybr Green Master Mix (Life Technologies) on 10 ng cDNA
template/reaction using exon-spanning primers. QuantiTect
Primer Assays were used for Il22, Reg3c and Reg3b. Other
primers are listed in Table S1. The Spearman’s rank correlation
coefficient among cytokine expression levels and inflammatory
parameters was determined using GraphPad Prism.
Results
Metabolic products from CBA L74 have a high anti-
inflammatory index
Probiotics or their metabolic products can induce a particular
type of cytokine profile depending on their inflammatory or anti-
inflammatory properties [21,22,23]. However, when probiotics or
their metabolic products have anti-inflammatory properties, their
activity is best appreciated when they are tested concomitantly
with a strong inflammatory agent [21]. To test the activity of
Lactobacillus paracasei CBA L74, we incubated human monocyte
derived dendritic cells (MoDCs) with either the live bacteria, or its
supernatant of culture after centrifugation and ultrafiltration in the
presence or absence of Salmonella typhimurium (FB62), which
induces a strong inflammatory response in DCs [21]. As shown in
Fig. 1A, while Salmonella induced a high production of the
inflammatory cytokine IL-12p70 and of the anti-inflammatory
cytokine IL-10, CBA L74 alone induced very little IL-12p70.
Culture supernatant of FB62 alone, but not of CBA L74, induced
some cytokine production by the MoDCs with higher IL-10 than
IL-12p70 (Fig. S1). However when tested together with Salmonella,
only the supernatant from CBA L74 had the ability to drastically
reduce IL-12p70 and increase IL-10 (Fig. 1A-B). The net result
was a strong anti-inflammatory index associated only to superna-
tant of CBA L74 when coincubated with Salmonella (Fig. 1C). By
contrast, the same anti-inflammatory activity was not observed
coincubating the DCs with Salmonella in the presence of the whole
CBA L74 bacteria (Fig. S1B). The anti-inflammatory effect of
CBA L74 sn was not due to inhibition of DC maturation (Fig.
S1C).
Consistent with our previous results on a different Lactobacillus
strain (B21090) [21], the activity was so strong that it was evident
at a concentration of 2% of supernatant of bacterial culture, which
is equivalent to the number of bacteria used to stimulate the DCs.
This suggests that in the short period of stimulation before
antibiotic killing, the bacteria are not able to release the metabolic
products in a sufficient amount to observe the anti-inflammatory
effect. Hence, metabolic products released by CBA L74 have
strong anti-inflammatory activity on DCs stimulated with Salmo-
nella.
Metabolic products of CBA L74 protect against colitis in
vivo
Probiotics have been proposed for the treatment or prevention
of inflammatory bowel disease, however only in pouchitis and
ulcerative colitis some beneficial effects were observed [18,24]. We
have shown that probiotics can be detrimental if administered to
inflamed tissues ex-vivo probably because of boosting an ongoing
inflammation, while postbiotics may be a safer alternative as they
can inhibit current inflammatory responses [20]. Hence, we
wanted to assess whether we could administer probiotics or
postbiotics to mice in order to prevent colitis development. Mice
were pretreated with either CBA L74 orally, or its culture
supernatant or unfermented culture medium intraperitoneally for
two days, and then received DSS into the drinking water to induce
colitis while on treatment. We decided to use the intraperitoneal
administration of the supernatant to avoid possible degradation of
the metabolic products due to transit in the stomach acidic
environment. Mice were followed for signs of colitis development
(body weight and presence of blood in feces). At the end of the
experiment mice were sacrificed and intestinal tissues were
collected for histological analysis. As shown in Fig. 2A, adminis-
Figure 2. Lactobacillus paracaseii CBA L74 supernatant ameliorates DSS colitis when administered intraperitoneally. Mice (n = 5) were
administered on a daily basis for 14 consecutive days (days22 to 11) with carbonate or live CBA L74 (109 CFU) intragastrically (ig) or with MRS or CBA
L74 supernatant (SN CBA L74) intraperitoneally (ip). Acute colitis was induced by dissolving 3% DSS in drinking water for 9 days (days 0–9). Panels
from left to right show weight curves of single mice, mean weight loss ad Kaplan-Meier survival for A. carbonate and live CBA L74 ig treated groups B.
MRS and CBA L74 supernatant (SN CBA L74) ip treated groups. C. Histological parameters for carbonate, MRS ip and SN ip treated groups. D.
Representative histologies for carbonate, MRS ip and SN ip treated groups. Arrows indicate ulcers, arrowheads lymphoid follicles and asterisks
inflammation. Bar size = 500 mm, magnification 50x. * p,0,05; ** p,0,01; *** p,0,001.
doi:10.1371/journal.pone.0087615.g002
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Figure 3. Fermented milk preparation has anti-inflammatory properties on MoDCs.MoDCs were infected with Salmonella FB62 (MOI 10:1)
for 1 hour in medium without antibiotics or in different infant formulas: non-fermented milk (NFM) and fermented milk (FM) obtained through
fermentation of Lactobacillus CBA L74 alone (CBA L74), fermentation in the presence S. thermophilus TH3 (S. th) or double fermentation with CBA L74
and S. thermophilus TH3 (CBA L74+S. th). After washing and 24 h incubations in medium with antibiotics cytokine abundance was evaluated. Panels
show % of response of IL-12p70 and IL-10 relative to MoDCs infected with SL1334 in medium without antibiotics. *** p,0,001.
doi:10.1371/journal.pone.0087615.g003
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tration of live bacteria to mice prior to DSS administration was
highly detrimental, as mice lost weight similarly to untreated
animals, but they all died in a few days. By contrast, intraperi-
toneal injection of CBA L74 fermented culture supernatant
resulted in protection against colitis by reducing weight loss and
favoring recovery of the mice (Fig. 2B). Also the unfermented
culture medium had some protective effect, but the effect of the
fermented medium was higher both as reduced weight loss, colitis
grade, lymphoid aggregates and number and size of ulcers
(Fig. 2C). Colitis score was assessed as described in material and
methods section. The histological analysis indicated that the tissue
of mice treated with CBA L74 fermented culture supernatant
Figure 4. Oral administration of fermented milk preparation protects against colitis. Mice (n = 5) were orally administered on a daily basis
for 14 consecutive days (days 22 to 11) with vehicle (water), non-fermented milk (NFM) or fermented milk (FM). Acute colitis was induced by
dissolving 3% DSS in drinking water for 9 days (days 0–9). A, Single mouse body weight curves, Kaplan-Meier survival and colon length for vehicle,
NFM and FM. B. Body weight curves (mean 6 SEM) for two pooled experiments. * p,0,05; ** p,0,01.
doi:10.1371/journal.pone.0087615.g004
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displayed a healthy morphology (Fig. 2D), whether this is due to a
better recovery or to protection against the inflammatory effects of
the DSS-induced colitis is difficult to ascertain at this time point.
However, the finding that mice lost weight similarly to the MRS
unfermented control medium but recovered faster would indicate
that an effect on the recovery phase may have occurred.
Hence, we found that CBA L74 fermented medium has anti-
inflammatory activity in vitro on DCs and has protective effect in
vivo against colitis.
Fermented milk powder preparations for infant formula
have anti-inflammatory properties in vitro
Having shown that CBA L74 fermentation leads to the
generation of anti-inflammatory metabolic products that protect
against colitis in vivo, we wanted to assess whether fermented food
that may be administered to healthy infants also retains similar
anti-inflammatory activity and whether this may result in
protection against colitis or infectious diseases. We first tested
whether reconstituted fermented milk powder preparations for
infant formula (FM) had similar anti-inflammatory activity on the
major immune cell targets that are the dendritic cells. To our
knowledge this is the first attempt to assess which cell types may be
the target of FM. MoDCs were incubated with reconstituted FM
or non-fermented milk powder for infant formula (NFM) and/or a
strong inflammatory infectious agent (Salmonella typhimurium) for
1 h and then thoroughly washed to eliminate any remaining milk
and to reduce the bacterial burden. Cells were then incubated in a
medium containing gentamycin to kill all the remaining Salmonella.
We used two different fermented formulations, one containing
only CBA L74 and another one with CBA L74 and S. thermophilus.
While both formulations of FM alone had no major cytokine-
inducing property (not shown), when coincubated with S.
typhimurium, they both reduced IL-12p70 production while
preserving the production of IL-10 by the dendritic cells (Fig. 3).
The anti-inflammatory index was very high and significantly
different from the one of the non-fermented milk (that was not
different from Salmonella alone) for both FM formulations (Fig. 3).
The two FM formulations did not statistically differ, even though
the one obtained with CBA L74 and S. thermophilus had greater
anti-inflammatory index. The anti-inflammatory activity of the
FM was not due to the dead bacteria present in the preparation as
NFM added with heat killed bacteria had no anti-inflammatory
properties (not shown).
Fermented milk for infant formula has protective effect
against colitis in vivo when administered orally
As shown earlier, DCs can be the target of the anti-
inflammatory activity of FM in vitro, similarly to what observed
with fermented culture medium. We then wondered whether also
FM had colitis protective effects in vivo. Mice received FM
(fermented with CBA L74 and S. thermophilus) or NFM by oral
gavage for 14 consecutive days (from day 22). Starting from day 0
they also received DSS in their drinking water for 9 days. Mice
were analyzed for development of colitis as reported above. As
shown in Fig. 4A–B, mice receiving FM lost less weight and
recovered faster than mice receiving vehicle or NFM. The mice all
survived DSS but the colon length was much higher for mice
receiving FM. Similar results were obtained with a preparation of
FM obtained only with CBA L74 fermentation (in the absence of
the starter S. thermophilus) indicating that the protective effects were
due to the metabolic activity of CBA L74 (Fig. 5A). In addition,
while the colitis score was very similar between the two groups,
mice receiving FM had much reduced numbers and size of ulcers
and lymphoid aggregates (Fig. 5B) and showed a better recovery of
the morphology of the tissue, as shown by histological analysis
(Fig. 5C).
We then analyzed whether we could observe differences in
cytokine expression in the intestines of mice pretreated with FM or
NFM that may explain the protective effect of FM. We found no
statistically significant differences in the two groups, but there was
a tendency to a reduction in Th1 polarization (as attested by
reduced expression of Tbet and IFN-c in intestinal cells) (Fig. 6).
There was also a slight reduction in IL-17a and Gata-3 expressing
cells. Interestingly, we observed a tendency towards an increase in
IL-33 and Cycloxygenase (Cox)-2 production in the FM group,
indicating that there is a concomitant reduction of pathologic
cytokines (IFN-c and IL-17a) and increase of protective factors
(IL-33 and Cox-2). However, when we analyzed the cytokine
expression in relation to the inflammatory parameters, we found
that some cytokines/transcription factors that were differentially
expressed between the two groups but that did not reach statistical
significance, were associated to the number of ulcers in a
statistically significant way. In particular, IL-33 was inversely
correlated to the number of ulcers (r Spearman 20.638, p= 0.048)
while T-bet, Gata-3 and IFN-c were directly correlated with the
number of ulcers (r Spearman 0.792, p= 0.011).
As, for experimental difficulties, the amount of FM that was
administered by gavage did not resemble the amount of FM an
infant would introduce with the formula, we decided to prepare a
special diet containing 5% of fermented milk. Mice were fed the
FM or NFM-containing diet for 14 days as before and were
treated with DSS starting from day 9 for 5 consecutive days. As
shown in Fig. S2, also increasing the amount of fermented milk
ingested via the diet we observed a drastic protection of mice from
DSS colitis. While 90% of the mice died when exposed to NFM
containing diet, only 30% of the mice died when fed with FM-diet
and they all recovered (Fig. S2).
FM for infant formula protects against a lethal dose of
Salmonella typhimurium infection
An important characteristic a FM should have, when thinking
to infant nutrition, is protection against enteric pathogens. One of
the major pathogen of the mouse gastrointestinal tract is Salmonella
typhimurium [25]. We wanted to test whether FM would protect
against S. typhimurium infection. We adopted two strategies: an
ex-vivo one, to strictly control the infection and to assess the direct
effect of the FM on intestinal tissue in response to Salmonella and an
in vivo one, using a mouse model of infection. In the experiments
ex-vivo, we used an organ culture model system established in our
laboratory that we can use to stimulate in a polarized fashion [20].
In fact we glue a cave cylinder on the apical face of the intestinal
mucosa that allows to confine the size of the infection and to avoid
spreading of bacteria on the broken edges of the tissue, thus
preserving tissue polarity and permitting physiological stimulation
Figure 5. Oral administration of CBA L74 fermented milk preparation protects against colitis. Mice (n = 5) were orally administered on a
daily basis for 14 consecutive days (days 22 to 11) with non-fermented milk (NFM) or milk fermented with only CBA L74 (FM). Acute colitis was
induced by dissolving 3% DSS in drinking water for 9 days (days 0–9). A. Single mouse body weight curves, Kaplan-Meier survival curve and colon
length for NFM and FM. B. Histological parameters. C. Representative histologies for NFM and FM. Arrows indicate ulcers, arrowheads lymphoid
follicles and asterisks inflammation. Bar size = 500 mm, magnification 50x. * p,0,05.
doi:10.1371/journal.pone.0087615.g005
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[20]. The cylinder is then excided and the tissue can be analyzed
for histology and the supernatant for cytokine production. We
found that FM could drastically reduce the amount of the
inflammatory cytokines KC (the equivalent of human IL-8), IL-6
and TNF-a, produced in response to Salmonella and to limit tissue
destruction (See Fig. 7A–B). In the experiments in vivo, we fed the
mice with a FM-containing diet for ten days and then challenged
the mice with a lethal dose of S. typhimurium. As shown in Fig. 7C,
mice receiving FM-diet died with a statistically significantly slower
kinetic than mice receiving NFM-diet, indicating a slight
protection against a lethal dose of Salmonella.
Discussion
In 2007 a concerted action between the world health
organization (WHO) and the UNICEF defined a ‘Global Strategy
for Infant and Young Child Feeding’ to raise awareness on the
importance of a proper nutrition for infants till the age of 5
(http://www.who.int/nutrition/topics/global_strategy/en/). In
this document it is highlighted the importance of facilitating
mothers to exclusively breastfeeding in the first 6 months of life.
If, for whatever reason, human milk becomes unavailable to an
infant, then during the first 6 months of life a new-generation
cows’ milk formula that is closer to the gold standard of human
milk should be used. Infant formulae are the only alternatives to
breast milk for infants who are unable to continue breastfeeding
through the first year of life [12].
In order to mimic some benefits observed in breast-fed infants,
functional ingredients such as fermented milk have been added to
infant formulae in recent years.
Even though there are several reports on the use of fermented
formula in infants, only a few studies have been carried out so far
to understand which are the immune cell targets of fermented milk
preparations (without live bacteria) for infant formula and what
are their major effects in vivo in animals in order to understand
their mechanisms of action. It has been shown that heat-treated
fermented formula (Bifidobacterium breve C50 and Streptococcus
thermophilus 065) does not interfere with the establishment of oral
tolerance but it strengthens the epithelial barrier properties [26].
Here, we compared the immunological properties of fermented
and non fermented milk for formula preparations. We found that
bacterial culture medium or milk fermented with L. paracasei CBA
L74 has strong anti-inflammatory properties on dendritic cells in
response to the inflammatory enteric pathogen Salmonella typhi-
murium. This indicates that during fermentation, L. paracasei CBA
L74 produces metabolites that play an important role in
controlling the dendritic cell response to inflammatory agents.
The DCs were capable of fully mature (both phenotypically and
morphologically) but were producing less IL-12p70 in response to
Salmonella, while IL-10 release was not affected. Overall, both CBA
L74-fermented culture medium and milk displayed a potent anti-
inflammatory index (the ratio between IL-10 and IL-12p70
production). We also tested if the dead bacteria (thus mimicking
the effect of killing bacteria by heat after fermentation) may be
responsible of the anti-inflammatory activity of the milk, but dead
L. paracasei was not influencing the inflammatory activity of
Salmonella. This has led us to test the effect of these metabolic
products also in vivo in mice after colitis induction or infection.
Interestingly, we found that CBA L74- fermented culture
medium could contrast the onset of colitis (there was a statistically
significant reduction in weight loss) and favor the recovery of mice
thus completely protecting them from colitis-induced death. Of
note, while the administration of fermented milk was protective,
the administration of live bacteria was detrimental, leading to mice
death. This has important implications when considering the use
of fermented formulas containing live probiotics, as these may be
dangerous when administered to a non-immune infant host.
When we tested the properties of fermented milk, we found that
it displayed protective effects against colitis when administered
intragastrically and this correlated with a reduced expression,
which was however not statistically significant, of the pathologic
Th1 cytokine IFN-c in the colons of treated mice. We also
observed a tendency to IL-33 increased production in mice fed
with FM. IL-33, a member of the IL-1 family, signals via the ST-2
receptor and is responsible for the polarization of Th2 T cells [27].
It is upregulated in patients with inflammatory bowel disease [28],
however whether it has pathological or protective effects is still a
matter of debate. Indeed, in some models of colitis the absence of
the IL-33/ST-2 axis is protective, suggesting a pathologic role of
IL-33 [29,30]; while in others the absence of IL-33 results in
reduced recovery and mouse death, indicating a protective role
[31,32]. Interestingly, the protective effect of IL-33 seems to be
exerted in the recovery phase [32], presumably via the activation
of Foxp3+ regulatory T cells [31]. Because we found an increase in
IL-33 during the recovery phase in the FM-treated group, it is
likely that this cytokine has a protective function in this phase,
however as this difference was not statistically significant we
cannot consider it as directly related to the overall anti-
inflammatory effect exerted by the fermented milk. We also
observed an increased but not statistically significant expression of
Cox-2 in the FM-treated group. Global deletion or chemical
inhibition of Cox-2 results in exacerbated colitis [33,34],
suggesting a protective role for Cox-2 during intestinal injury.
Hence, small differences towards reduction of pro-inflammatory
IFN-c producing cells and increase of protective cytokines (IL-33)
or enzymes (Cox-2) may be responsible for the overall protective
effect of FM against colitis and may not reach statistical
significance when considered individually. The colitis-protective
effect was observed also when the fermented milk powder was
added to the pellet diet. By contrast the non-fermented milk did
not display any protective effect suggesting that the fermentation
in itself is responsible for the observed effect.
Another important characteristic of breast milk is that it can
protect against enteric pathogens. This characteristic is often
associated to the IgAs that are passively delivered to the pups via
the milk [35,36]. However, it is also possible that milk-associated
microbiota [37] or its metabolic products may reinforce the
epithelial barrier or the immune system against pathogens. By
comparing mice fed with fermented or non-fermented milk
preparations, we could address this issue as there are no mother-
derived IgAs, and analyze if fermented milk could protect against
enteric infections. We found that mice fed with the fermented milk
preparation displayed a slightly longer survival to a lethal dose of
Salmonella. This indicates that L. paracasei CBA L74 metabolic
products released in the milk have enteric pathogen protective
effects. Indeed, the exposure of colon explants to a fermented milk
Figure 6. CBA L74 fermented milk reduces inflammatory mediators expression. At the end of the experiment described in Figure 5 RNA
was extracted from colons and expression levels of Tbet, Gata3, Inf-c, Il-17a, Il-6, Il-22, Il-33, Il-1b, Kc, Ccl2, Cox2, iNos, Ahr, Indo, Zo-1, Reg3b, Reg3c
were assessed by RT-qPCR. Expression levels are normalized to the housekeeping mRNA Ralp32. Dots represent individual mice measurements, lines
represent the average value.
doi:10.1371/journal.pone.0087615.g006
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preparation resulted in a reduced capacity of the pathogen to
cause inflammation and tissue destruction. Whether the latter
effect is a consequence of the reduced inflammation or the reduced
capacity of Salmonella to infect the tissue remains to be established.
We also do not know whether the fermented products are
strengthening the barrier properties of the epithelium besides
reducing the inflammation.
The capacity of postbiotics to protect against colitis or pathogen
infection has been reported also for other bacterial strains.
Lactobacillus brevis SBC8803 derived polyphosphate is capable of
protecting mice against DSS-induced colitis, acting on the p38
MAPK pathway and suppressing intestinal permeability induced
by oxidants [38]. The p40 molecule, produced and secreted by
Lactobacillus GG, is the main mediator for ameliorating DSS and
oxazolone-induced inflammation, through its binding to EGFR.
Activation of EGFR by p40 was sufficient to reduce cytokine-
induced IEC apoptosis in vitro and ex-vivo [39]. Lactobacillus gasseri
OLL 2716 and Propionibacterium freudenrichii ET-3 fermentation
metabolites can increase the number of CD4 and CD8 lympho-
cytes in blood and the capacity of macrophages to produce nitric
oxide and reactive oxygen species [40]. Consistently, we have
observed that L. paracasei strain B21060 has preventive effect in the
DSS colitis model [21], but is detrimental when applied on
intestinal mucosal explants from IBD patients, whereas the culture
supernatant exerts a prominent anti-inflammatory effect on the
explants from the same patients [20]. However, to our knowledge
this is the first study addressing the effect of fermented milk
metabolites on dendritic cells or on inflammatory responses in vivo.
We have not yet identified, the compound/s of the culture
supernatant or of the fermented milk having the protective effect
and we also do not know whether they are the same in the two
fermentations. Further studies are needed to characterize the
nature of the compound/s and to identify their molecular
structure.
In conclusion, we have shown that L. paracasei CBA L74
fermented milk preparations for infant formula have a strong anti-
inflammatory activity in vitro and protect against colitis or enteric
pathogens in vivo. This opens new perspectives in infant nutrition
and suggests that L. paracasei CBA L74 fermented formula can
provide some immune benefits to formula-fed infants, without
carrying potentially dangerous live bacteria.
Supporting Information
Figure S1 A. MoDCs were incubated for 1 h with CBA L74
supernatant (Sn CBA L74), FB62 supernatant (Sn FB62), MRS or
LB. After washing and 24 h incubations, concentrations of IL-
12p70 and IL-10 were determined by ELISA and CBA assays.
Concentrations are shown as % of response relative to untreated
MoDCs. B. MoDCs were infected with either Salmonella FB62
(MOI 10:1) or Lactobacillus CBA L74 (MOI 10:1) for 1 hour in
medium without antibiotics or in the presence of CBA L74
supernatant (Sn CBA L74). After washing and 24 h incubations in
medium with antibiotics, cytokine abundance was evaluated. C.
MoDCs were infected for 1 h with either Salmonella FB62 (MOI
10:1) or Lactobacillus CBA L74 (MOI 10:1) for 1 hour in medium
without antibiotics, washed, incubated for 24 h and analysed at
FACS for CD83 and HLA-DR surface markers. * p,0,05; ***
p,0,001.
(EPS)
Figure S2 Diet containing fermented milk protects against
colitis. Mice (n = 10) were fed with modified diet containing 5% of
non-fermented milk (NFM) or fermented milk (FM). After 10 days
acute colitis was induced by 9-day administration of DSS 3% in
drinking water. Panels show single mouse weight curves, weight
curves (mean 6 SEM) and Kaplan-Meier survival for NFM and
FM. * p,0,05; *** p,0,001.
(EPS)
Table S1 List of forward and reverse primers used for Q-PCR of
the reported genes.
(PDF)
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